What’s holding back aging biomarkers?
Despite growing excitement, most aging biomarkers today remain clinically irrelevant. This piece dives into the real bottleneck: our data. It maps the missing datasets, outlines what’s actually needed for biomarker validation, and proposes a path forward—designed to help researchers, biotech, and funders unlock real-world impact in aging therapeutics.